Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02611908
Title Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Choi
Indications
Therapies
Age Groups: adult
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field